Drug intelligence / Profile preview

111In-PSMA I&T

Development stage
Phase 2
Lead developer
Scintomics
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules, Peptides
Administration
Intravenous
01

Overview

111In-PSMA I&T is an investigational radiopharmaceutical consisting of the prostate-specific membrane antigen (PSMA)-targeting peptidomimetic ligand zadavotide guraxetan (PSMA I&T) labeled with the gamma-emitting radionuclide indium-111. It is designed for single-photon emission computed tomography (SPECT/CT) imaging and radioguided surgery (RGS) in patients with prostate cancer, including newly diagnosed, recurrent, and metastatic disease. By binding specifically to PSMA overexpressed on prostate cancer cells, 111In-PSMA I&T allows for the precise intraoperative localization and resection of metastatic lymph nodes and other soft-tissue lesions using a handheld gamma probe.

Other names
[111In]PSMA-I&T111In-PSMA-I&T111In-labeled PSMA-I&T111In-zadavotide guraxetanindium (111In) zadavotide guraxetanindium In 111 zadavotide guraxetanindium-111 PSMA I&Tindium-111-PSMA-I&T
02

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 111In-PSMA I&T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 111In-PSMA I&T.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call